List of Abstracts

List of abstracts selected for oral or poster presentation.

Abstract submission is now closed, but late submissions can be considered for poster presentation. Please contact the conference manager at for late submission.

Abstracts selected for oral presentations:

  • Sofia Aakko (Faron Pharmaceuticals, Finland ): “Ex vivo immune activation with the macrophage-targeting immunotherapy, anti-Clever-1 antibody bexmarilimab, in acute myeloid leukemia and myelodysplastic syndrome”
  • Katie Dunphy (Maynooth University,Ireland): “Understanding extramedullary multiple myeloma using quantitative proteomics”
  • Arjen Gebraad (Tampere University, Finland): ”Bone Marrow and Adipose Tissue Stem/Stromal Cells as Pericytes Generate Distinct Vascular Phenotypes”
  • Merja Heinäniemi (University of Eastern Finland, Finland): ”Mechanistic study of Wee1 kinase inhibition with AZD1775 exposes drug targetable vulnerabilities in acute B-lymphoblastic leukemia”
  • Petra Nygren (University Of Helsinki, Finland): “High-throughput evaluation of the potential of cancer drugs to enhance natural killer cell cytotoxicity in hematological malignancies”
  • Joseph Saad (Institute for Molecular Medicine Finland - FIMM, Helsinki Institute of Life Science - HiLIFE, University of Helsinki): ”Monosomy 7 and del(7q) Cause Selective Sensitivity to Inhibitors of Nicotinamide Phosphoribosyltransferase in Acute Myeloid Leukemia”
  • Imre Västrik (Institute for Molecular Medicine Finland – FIMM, Finland): ”Functional precision medicine data platform”
  • Alexander Waclawiczek (German Cancer Research Center, Germany): ”Flow cytometry-based combinatorial BCL-2 family expression in Acute Myeloid Leukemia Stem Cells predicts clinical response to Venetoclax and other BH3-mimetics”

Abstracts selected for poster presentation:

  • Sadiksha Adhikari (University of Helsinki, Finland): “CYLD as a biomarker for resistance to immunomodulatory treatments in multiple myeloma”
  • Andres Blanco (University of Pennsylvania, United States): “Targeting epigenetic regulators to override cellular identity programs and induce therapeutic differentiation in MLL-rearranged acute myeloid leukemia”
  • Kieran Brennan (University College Dublin, Ireland): “Multiple Myeloma Plasma Extracellular Vesicles from patients treated with Daratumumab show elevated levels of complement inhibitory proteins CD55 and CD59”
  • Anthony Brown (St. Jude Children's Research Hospital, United States): “Development of an Imaging-based Platform for Ex Vivo Drug Sensitivity Testing of Acute Lymphoblastic Leukemia”
  • Anna Dolnik (Charité University Medicine Berlin, Germany): “Combined CRISPR-Cas9 targeted enrichment and whole genome sequencing profiling allows real time stratification of acute myeloid leukemia (AML)”
  • Hanna Duàn (University of Helsinki, Finland): “Ex vivo modeling of NK cell immunotherapy response in acute myeloid leukemia using single-cell transcriptomics”
  • Kat Ginda-Mäkelä (Applied Cells Inc., United States): “A New Approach for High Recovery and Purity Isolation of Plasma Cells from Whole Blood and Bone Marrow”
  • Konstantin Ivanov (University of Eastern Finland, Finland): “Deep variational autoencoder modeling of multimodal single-cell data resolves molecular fingerprints of pre-leukemic states”
  • Niveditha Umesh Katyayini (Oslo universitetssykehus - Norwegian Radium Hospital, Norway): “The LD-VenEx phase II clinical trial: An ex vivo flow cytometry based-drug screening of AML patient samples”
  • Elmira Khabusheva (University of Helsinki, Finland): “HDAC inhibitors resensitize AML cells to the BCL-2 and BCL-2/BCL-xL inhibitors venetoclax and navitoclax”
  • Olga Krali (Uppsala University, Sweden): “A multiscale machine learning approach for molecular subtype determination of pediatric acute lymphoblastic leukemia”
  • Romika Kumari (Institute for Molecular Medicine Finland, Finland): “CD8+ effector and memory T-cells are associated with venetoclax sensitivity in acute myeloid leukemia”
  • Adriana Ladungova (CEITEC, Masaryk University, Czech Republic): “Prediction of novel treatment options for venetoclax-resistant AML cells based on drug repurposing”
  • Mari Lahnalampi (University of Eastern Finland, Finland): “Dynamic evolution of TCF3-PBX1 leukemias at the single-cell level under chemotherapy pressure”
  • Timofey Lebedev (Engelhardt Institute of Molecular Biology, Russian Federation): “Prediction of novel drug targets for pediatric acute leukemias by combining transcriptome, gene fitness and drug action data”
  • Alina Malyutina (University of Helsinki, Finland): “Multi-omics data integration reveals molecular targets of carfilzomib resistance in multiple myeloma”
  • Mehdi Mirzaie (University of Helsinki, Finland): “Drug combinations for acute myeloid leukemia”
  • Laura Oksa (Tampere University, Finland): “Genomic Determinants of Therapy Response in Etv6-Runx1 Leukemia”
  • Jani Saarela (University of Helsinki / FIMM,Finland): “Ex vivo Drug Sensitivity Testing of Primary Cells for Functional Precision Medicine”
  • Philipp Sergeev (FIMM, Finland): “Single Cell RNA Sequencing Identifies Potential Molecular Indicators of Response to Melflufen in Multiple Myeloma”
  • Rebecca Sheridan (University College Dublin, Ireland): “Analysis of Multiple Myeloma Extracellular Vesicles uptake by bone marrow microenvironment cells and characterisation downstream cytokine release”
  • Ankita  Srivastava (University of Helsinki, Finland): “Deciphering plasma cell heterogeneity and tumor microenvironment in light-chain amyloidosis using single-cell RNA-sequencing" 
  • Nona Struyf (Karolinska Institute, Sweden): “Comparison of data from fresh and frozen AML samples for functional drug testing”
  • Silja Tammi (Finnish Red Cross Blood Service , Finland): “Finnish Hematology Registry and Biobank (FHRB): a national population-based comprehensive biobank resource for hematological research”
  • Sylvain Tollis (University of Eastern Finland, Finland): “Towards a mechanistic understanding of cell-cycle rewiring during hematopoietic differentiation: insight from single cell transcriptomics and quantitative live-cell imaging”
  • Dimitrios Tsallos (Institute For Molecular Medicine Finland – FIMM,Finland): “Resistance to the proteasome inhibitor bortezomib is associated with a gain in sensitivity to BCL-xL inhibition in multiple myeloma”
  • Tania Vu (Knight Cancer Institute, Oregon Health and Science University, United States): "Evaluating Immune-Oncology-Small Molecule Drug Responsesin Individual AML Patients by Single Cell Functional Precision Imaging"